Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 8, 2017, Atara Biotherapeutics, Inc. (the Company) held
its annual meeting of stockholders (the Annual Meeting).The
following is a brief description of each matter voted upon at the
Annual Meeting, as well as the number of votes case for or
against each matter and the number of abstentions and broker
non-votes with respect to each matter.A more complete description
of each matter is described in more detail in the Companys
definitive proxy statement filed with the Securities and Exchange
Commission on April 25, 2017 (the Proxy Statement).
|
1. |
Election of Directors |
|
Nominee |
For |
Withheld |
Broker Non-Votes |
|
Isaac Ciechanover, M.D. |
23,823,217 |
469,559 |
1,967,538 |
|
Carol Gallagher, Pharm.D. |
23,364,751 |
928,025 |
1,967,538 |
The Companys stockholders elected each of the two nominees for
director to serve until the 2020 annual meeting of stockholders
and until his or her respective successor is elected.
|
2. |
Ratification of Appointment of Independent Registered |
|
For |
Against |
Abstentions |
|
26,259,274 |
1,040 |
The Companys stockholders ratified the appointment of Deloitte
Touche LLP as the Company’s independent registered public
accounting firm for the fiscal year ending December 31, 2017.
No other matters were submitted for stockholder action.
About Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. Its T-cell product candidates include Epstein Barr Virus-cytotoxic T lymphocytes (EBV-CTL), which is in Phase II clinical trials for malignancies associated with EBV; cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1. Its molecularly targeted product candidates include STM 434, which is in Phase I clinical trial of STM 434 for ovarian cancer and other solid tumors; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-Actin-related protein 2-A (ActR2A)/2B monoclonal antibody; STM 217; ActR2B5, and ATA 842, a humanized antibody targeting myostatin.
